The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.
“GLP-1RA exposure in patients with dementia was associated with lower all-cause mortality in this large real-world cohort,” reported lead author Dr Ana Carolina Gomes from Hospital Alemão Oswaldo Cruz and Paulista Cognition Center, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil.
In this study, Gomes and her team used the TriNetX Global Collaborative Network to identify patients with dementia (ie, Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, or dementia with Lewy bodies). They then stratified eligible individuals by exposure or nonexposure to GLP-1RA.
The index event was defined as the first recorded diagnosis of dementia, with outcomes assessed after a wash-in period of 180 days.
Gomes and colleagues balanced the cohorts in a 1:1 ratio via propensity score matching (PSM) for demographics, neurological and systemic comorbidities, metabolic conditions including diabetes mellitus, and central nervous system medication use. All-cause mortality was the primary outcome.
A total of 4,940 patients were assigned in each cohort following PSM, with “excellent balance at baseline including diabetes prevalence,” according to the authors.
The rate of all-cause mortality was significantly lower in patients with dementia exposed to GLP-1RA than those with no exposure (18.2 percent vs 21.1 percent; risk difference, ‒2.9 percent, 95 percent confidence interval [CI], ‒4.6 to ‒1.3). [AAIC 2026, abstract 10008]
In Kaplan-Meier analysis, use of GLP-1RA was associated with a 33-percent lower risk of mortality (hazard ratio, 0.67, 95 percent CI, 0.61‒0.74; log-rank p<0.001), with a longer median survival in the exposed group.
“These exploratory findings highlight a potential interaction between metabolic therapies and neurological outcomes,” said Gomes.
Neuroprotection
These results are also consistent with previous studies reporting the beneficial effects of using GLP-1RAs in preventing AD.
A recent study by Tang and colleagues found that exposure to GLP-1RAs, as well as sodium-glucose cotransporter-2 (SGLT2) inhibitors, could reduce the risk of AD and related dementia when compared with other second-line glucose-lowering medications among patients with type 2 diabetes. [JAMA Neurol 2025;82:439-449]
Similar findings were reported in a study by Nowell and colleagues, in which the use of GLP-1RA or SGLT2 inhibitor significantly correlated with a lower risk of AD. [Alzheimers Dement 2025;21:e70639]
These results, together with those of the current study, show the potential neuroprotective effects of GLP-1RAs and underscore their possible role in strategies for preventing AD and dementia.
In future studies, Gomes and her team suggested that researchers improve exposure definitions, stratify patients by dementia subtype, and examine metabolic and vascular effect modifiers.
“Metabolic dysfunction is increasingly recognized as a modifier of neurodegenerative disease progression,” Gomes said. “GLP1-RAs have been proposed as modulators of neuroinflammation, vascular risk, and systemic resilience through direct central nervous system receptor activity.”